CAPLIN POINT LABORATORIES (CAPLIPOINT-IN)
Pharma. & Medical Research / Pharmaceuticals / Pharmaceuticals

Last Close 1,097.50 (INR)
Avg Daily Vol 77,047
52-Week High 1,143.95
Trailing PE 21.9
Annual Div 4.50
ROE 24.4%
LTG Forecast --
1-Mo Return 1.6%

2023 November 08
NSE Exchange
Market Cap 80.0B
52-Week Low 575.00
Forward PE 18.0
Dividend Yield 0.4%
Annual Rev 15.2B
Inst Own 1.7%
3-Mo Return 10.2%

AVERAGE SCORE
NEUTRAL OUTLOOK: CAPLIPOINT's current score is relatively in-line with the market.

HIGHLIGHTS
- The score for Caplin Point Laboratories has been on a negative trend from 10 to 7 over the past 15 weeks.
- In the past 3 years, the best score was 10 on 2023-07-30, and the worst score was 6 on 2023-05-28.

PRICE AND VOLUME CHARTS

1-Year Return: 48.8%
5-Year Return: 154.0%

BUSINESS SUMMARY
Caplin Point Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicalcs and sachets (liquids and powders). It also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. It has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Company's subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.
INDICATOR COMPONENTS

The **AVERAGE SCORE** combines the quantitative analysis of five widely-used investment decision making tools: Earnings, Fundamental, Relative Valuation, Risk, and Price Momentum. A simple average of the underlying component ratings is normally distributed to rank stocks on a 1-10 scale (10 being awarded to the most favorable). These factors may be evaluated differently using alternative methodologies and the importance of individual factors varies across industries, market capitalization and investment styles. Additional criteria should always be used to evaluate a stock.

### PEER ANALYSIS

<table>
<thead>
<tr>
<th>Ticker</th>
<th>Price (2023-11-08)</th>
<th>1-Mo Return</th>
<th>3-Mo Return</th>
<th>1-Yr Return</th>
<th>Market Cap</th>
<th>Trailing PE</th>
<th>Forward PE</th>
<th>Dividend Yield</th>
<th>Net Margin</th>
<th>LGT Forecast</th>
<th>I/B/E/S Mean</th>
<th># of Analysts</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZYDUSLIFE</td>
<td>625.20</td>
<td>3.6%</td>
<td>-4.6%</td>
<td>38.6%</td>
<td>592.0B</td>
<td>23.8</td>
<td>19.7</td>
<td>0.96%</td>
<td>15.1%</td>
<td>--</td>
<td>--</td>
<td>29</td>
</tr>
<tr>
<td>AJANTPHARM</td>
<td>1,801.25</td>
<td>3.1%</td>
<td>2.9%</td>
<td>44.5%</td>
<td>229.9B</td>
<td>35.1</td>
<td>29.2</td>
<td>0.85%</td>
<td>16.9%</td>
<td>--</td>
<td>--</td>
<td>13</td>
</tr>
<tr>
<td>GLENMARK</td>
<td>785.95</td>
<td>-0.96%</td>
<td>-4.7%</td>
<td>85.8%</td>
<td>210.7B</td>
<td>69.9</td>
<td>20.6</td>
<td>0.32%</td>
<td>1.9%</td>
<td>--</td>
<td>--</td>
<td>13</td>
</tr>
<tr>
<td>SANOFI</td>
<td>7,780.20</td>
<td>6.0%</td>
<td>6.2%</td>
<td>38.3%</td>
<td>175.6B</td>
<td>28.9</td>
<td>30.0</td>
<td>2.5%</td>
<td>20.5%</td>
<td>--</td>
<td>--</td>
<td>5</td>
</tr>
<tr>
<td>PGHL</td>
<td>5,154.45</td>
<td>1.3%</td>
<td>-2.5%</td>
<td>22.0%</td>
<td>85.3B</td>
<td>37.1</td>
<td>--</td>
<td>1.8%</td>
<td>18.7%</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>CAPLIPOINT</td>
<td>1,097.50</td>
<td>1.6%</td>
<td>10.2%</td>
<td>48.8%</td>
<td>80.0B</td>
<td>21.9</td>
<td>18.0</td>
<td>0.41%</td>
<td>26.0%</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>STAR</td>
<td>487.30</td>
<td>-2.6%</td>
<td>10.6%</td>
<td>48.8%</td>
<td>43.5B</td>
<td>--</td>
<td>23.3</td>
<td>0.31%</td>
<td>-6.0%</td>
<td>--</td>
<td>--</td>
<td>2</td>
</tr>
<tr>
<td>WOCKPHARMA</td>
<td>240.25</td>
<td>4.7%</td>
<td>-6.6%</td>
<td>0.54%</td>
<td>34.4B</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>-32.3%</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>AMRUTANJAN</td>
<td>603.60</td>
<td>-1.9%</td>
<td>-4.8%</td>
<td>-18.0%</td>
<td>17.5B</td>
<td>41.2</td>
<td>--</td>
<td>0.76%</td>
<td>11.2%</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>GUJTHEM</td>
<td>199.75</td>
<td>-3.8%</td>
<td>23.3%</td>
<td>35.4%</td>
<td>15.8B</td>
<td>26.1</td>
<td>--</td>
<td>0.54%</td>
<td>37.7%</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>THEMISMED</td>
<td>169.50</td>
<td>-10.1%</td>
<td>7.6%</td>
<td>88.7%</td>
<td>14.5B</td>
<td>23.2</td>
<td>--</td>
<td>0.29%</td>
<td>16.2%</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Average</td>
<td>1,722.27</td>
<td>0.08%</td>
<td>3.4%</td>
<td>39.4%</td>
<td>136.3B</td>
<td>34.1</td>
<td>23.5</td>
<td>0.88%</td>
<td>12.3%</td>
<td>--</td>
<td>--</td>
<td>10.5</td>
</tr>
</tbody>
</table>

### PEER COMPANIES

<table>
<thead>
<tr>
<th>Ticker</th>
<th>Company Name</th>
<th>Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZYDUSLIFE</td>
<td>Zydus Lifesciences</td>
<td>Pharmaceuticals</td>
</tr>
<tr>
<td>AJANTPHARM</td>
<td>Ajanta Pharma</td>
<td>Ajanta Pharma</td>
</tr>
<tr>
<td>GLENMARK</td>
<td>Glenmark Pharmaceuticals</td>
<td>Glenmark Pharmaceuticals</td>
</tr>
<tr>
<td>SANOFI</td>
<td>Sanofi India</td>
<td>Sanofi Pharma</td>
</tr>
<tr>
<td>STAR</td>
<td>Strides Pharma Science</td>
<td>Star</td>
</tr>
<tr>
<td>AMRUTANJAN</td>
<td>Amrutanjan Health Care</td>
<td>Amrutanjan Health Care</td>
</tr>
<tr>
<td>WOCKPHARMA</td>
<td>Wockhardt</td>
<td>Wockhardt</td>
</tr>
<tr>
<td>GUJTHEM</td>
<td>Gujarat Themis Biosyn</td>
<td>Gujarat Themis Biosyn</td>
</tr>
<tr>
<td>THEMISMED</td>
<td>Themis Medicare</td>
<td>Themis Medicare</td>
</tr>
<tr>
<td>PGHL</td>
<td>Procter &amp; Gamble Health</td>
<td>Procter &amp; Gamble Health</td>
</tr>
</tbody>
</table>

Note: The table above lists the price, return, market cap, and other financial metrics for each company, along with their respective stock grades and number of analysts following each stock.
CAPLIN POINT LABORATORIES (CAPLIPOINT-IN)
Pharma. & Medical Research / Pharmaceuticals / Pharmaceuticals

EARNINGS

NEUTRAL OUTLOOK: Mixed earnings expectations and performance.

Pharmaceuticals Group: 5.1
Mid Market Cap: 5.5
Pharma. & Medical Research Sector: 4.8
BSE Sensex Index: 6.7

Earnings Score Averages
Peers

<table>
<thead>
<tr>
<th></th>
<th>-6M</th>
<th>-3M</th>
<th>-1M</th>
<th>-1W</th>
<th>Current</th>
<th>1Y Trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAPLIPOINT</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>STAR</td>
<td>6</td>
<td>3</td>
<td>5</td>
<td>5</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>SANOFI</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>PGHL</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>WOCKPHARMA</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td></td>
</tr>
</tbody>
</table>

Currency in INR

Earnings Score Trend (4-Week Moving Avg)

Earnings Surprises

- Positive: 7
- Neutral: 6
- Negative: 2
- No Rating: NR

Estimate Revisions

- Positive: 7
- Neutral: 6
- Negative: 2
- No Rating: NR

Recommendation Changes

- Positive: 7
- Neutral: 6
- Negative: 2
- No Rating: NR

Last 4 Years

- # Positive Surprises (>2%): 2
- # Negative Surprises (<-2%): 1
- # In-Line Surprises (within 2%): 1
- Avg Surprise: -0.48%

Last 4 Weeks

- # Up Revisions: 0
- # Down Revisions: 0
- Avg Up Revisions: 0.00%
- Avg Down Revisions: 0.00%

Last 120 Days

- # Broker Upgrades: 0
- # Broker Downgrades: 0

HIGHLIGHTS

- Caplin Point Laboratories currently has an Earnings Rating of 7. The average Earnings Rating for its Pharmaceuticals industry is 5.1 and the S&P BSE SENSEX index average is 6.7.
- Over the past 90 days, the consensus price target for CAPLIPOINT has increased notably from 908.00 to 1,010.00, a gain of 11.2%.
- There have been no upward or downward broker recommendation changes for Caplin Point Laboratories over the past 120 days.

PRICE TARGET

- The chart indicates where analysts predict the stock price will be within the next 12 months, as compared to the current price.

12-Month Price Target

| Mean (INR) | 1,010.00 |
| High      | 1,160.00 |
| Low       | 865.00   |
| Target vs. Current | -8.0% |
| # of Analysts | 2         |

© 2023 Refinitiv, an LSEG business. All rights reserved.
EARNINGS PER SHARE

Earnings per share (EPS) is calculated by dividing a company’s earnings by the number of shares outstanding. Analysts tend to interpret a pattern of increasing earnings as a sign of strength and flat or falling earnings as a sign of weakness.

The charts provide a comparison between a company’s actual and estimated EPS, including the high and low forecasts.

MEAN ESTIMATE TREND

<table>
<thead>
<tr>
<th>Q</th>
<th>Q</th>
<th>Y</th>
<th>Y</th>
<th>Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current</td>
<td>--</td>
<td>--</td>
<td>59.800</td>
<td>68.300</td>
</tr>
<tr>
<td>30 Days Ago</td>
<td>--</td>
<td>--</td>
<td>59.800</td>
<td>68.300</td>
</tr>
<tr>
<td>90 Days Ago</td>
<td>--</td>
<td>--</td>
<td>53.850</td>
<td>61.200</td>
</tr>
<tr>
<td>% Change (90 Days)</td>
<td>--</td>
<td>--</td>
<td>11.0%</td>
<td>11.6%</td>
</tr>
</tbody>
</table>

# of Analysts: 1

ANALYST RECOMMENDATIONS

I/B/E/S Mean: Strong Buy (1 Analyst)

<table>
<thead>
<tr>
<th>Strong Buy</th>
<th>Buy</th>
<th>Hold</th>
<th>Sell</th>
<th>Strong Sell</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

EARNINGS SURPRISES

Comparing a company's actual earnings to the mean expectation of analysts results in a difference referred to as a 'positive' or 'negative' surprise. Research has shown that when a company reports a surprise, it is often followed by more of the same surprise type.

Surprise Summary (Last 6 Years)

<table>
<thead>
<tr>
<th>Surprise Type</th>
<th>Amount</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive Years (&gt; 2%)</td>
<td>4</td>
<td>66.7%</td>
</tr>
<tr>
<td>Negative Years (&lt; -2%)</td>
<td>1</td>
<td>16.7%</td>
</tr>
<tr>
<td>In-Line Years (within 2%)</td>
<td>1</td>
<td>16.7%</td>
</tr>
</tbody>
</table>

ANNUAL REVENUE

A pattern of increasing sales in conjunction with a rising EPS may influence a buy recommendation, while flat or falling sales and faltering earnings may explain a sell recommendation. A rising EPS with flat or falling sales may result from increased cost efficiency and margins, rather than market expansion. This chart shows the sales forecast trend of all analysts and the highest and lowest projections for the current and next fiscal year.
**FUNDAMENTAL NEUTRAL OUTLOOK:** Fundamentals relatively in-line with the market.

**Fundamental Score Averages**
- Pharmaceuticals Group: 5.1
- Mid Market Cap: 6.2
- Pharma. & Medical Research Sector: 5.1
- BSE Sensex Index: 7.1

<table>
<thead>
<tr>
<th>Peers</th>
<th>Q4 2022</th>
<th>Q1 2023</th>
<th>Q2 2023</th>
<th>Q3 2023</th>
<th>Current</th>
<th>3Y Trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>PGHL</td>
<td>9</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>CAPLIPOINT</td>
<td>9</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>SANOFI</td>
<td>7</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>WOCKPHARMA</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>STAR</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

**FUNDAMENTAL INDICATORS**

<table>
<thead>
<tr>
<th></th>
<th>Profitability (25% weight)</th>
<th>Debt (25% weight)</th>
<th>Earnings Quality (25% weight)</th>
<th>Dividend (25% weight)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>PGHL 10</td>
<td>PGHL 10</td>
<td>PGHL 8</td>
<td>PGHL 10</td>
</tr>
<tr>
<td></td>
<td>CAPLIP 9</td>
<td>SANOFI 9</td>
<td>SANOFI 8</td>
<td>SANOFI 9</td>
</tr>
<tr>
<td>Neutral</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>SANOFI WOCKP 3</td>
<td>STAR WOCKP 3</td>
<td>STAR WOCKP 3</td>
<td>STAR WOCKP 3</td>
</tr>
<tr>
<td>Negative</td>
<td>2</td>
<td>4</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>STAR WOCKP 2</td>
<td>CAPLIP 4</td>
<td>CAPLIP 4</td>
<td>CAPLIP 4</td>
</tr>
<tr>
<td>No Rating</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

| Revenue Growth    | 15.2%                        | Current Ratio     | 5.8                           | Oper. Cash Yield     | -24.6%                  | Dividend Growth | 12.5% |
|                   | For year over year ending 2023-06 | For interim period ending 2023-03 | 0.0% | For latest 12 months ending -- | Accruals 28.5% | For latest 12 months ending 2023-06 |
| Gross Margin      | 49.7%                        | Debt-to-Capital   | 0.0%                          | Interest Funding     | 0.2%                    | Dividend Payout | 8.7%  |
|                   | For latest 12 months ending 2023-06 | For annual period ending 2023-03 | 0.0% | For annual period ending 2023-03 | Days Sales In Inv. 135.4 | For latest 12 months ending 2023-06 |
| Return On Equity  | 24.4%                        | Interest Coverage | 454.5                         | Days Sales In Rec.   | 124.4                   | Dividend Coverage | 13.2  |
|                   | For interim period ending 2023-03 | For interim period ending 2023-06 | 0.0% | For annual period ending 2023-03 | For latest 12 months ending 2023-03 |          |
| Net Margin        | 26.0%                        | Days Sales In Rec. | 124.4                         | Current Div. Yield   | 0.4%                    | Current Div. Yield | 0.4%  |
|                   | For latest 12 months ending 2023-06 | For annual period ending 2023-03 | 0.0% | For latest 12 months ending 2023-11 |                            |          |

**HIGHLIGHTS**
- Caplin Point Laboratories currently has a Fundamental Rating of 7. The average Fundamental Rating for its Pharmaceuticals industry group is 5.1 and the S&P BSE SENSEX index average is 7.1.
- The company's gross margin has been higher than its industry group average for each of the past five years.
- The company's current ratio has been higher than its industry group average for each of the past five years.
- CAPLIPONI's operating cash yield of -24.6% is substantially below the Pharmaceuticals industry group average of -0.22%.
- Of the 191 firms within the Pharmaceuticals industry group, Caplin Point Laboratories is among 87 companies that pay a dividend. The stock's dividend yield is currently 0.42%.
CAPLIN POINT LABORATORIES (CAPLIPOINT-IN)
Pharma. & Medical Research / Pharmaceuticals / Pharmaceuticals

HIGHLIGHTS
- Caplin Point Laboratories currently has a Relative Valuation Rating of 5 while the S&P BSE SENSEX Index has an average rating of 5.6.
- CAPLIPOINT's Price to Sales ratio and Trailing P/E are both significantly above (more expensive than) their 5-year averages.
- Based on Price to Sales, CAPLIPOINT currently trades at a 26% Premium to its Pharmaceuticals industry group peers. On average, the company has traded at a 19% Premium over the past five years.
- Based on Trailing P/E, CAPLIPOINT currently trades at a 40% Discount to its Pharmaceuticals industry group peers. On average, the company has traded at a 41% Discount over the past five years.
- CAPLIPOINT's Forward P/E of 18.0 represents a 12% Premium to its 5-year average of 16.1.
PRICE TO SALES
The most recent week's close price divided by the revenue per share.

Price to Sales: 5.3
5-Year Average: 4.3
BSE Sensex Index Average: 3.4
Pharmaceuticals Group Average: 4.2

TRAILING PE
The most recent week's close price divided by the sum of the four most recently reported quarterly earnings.

Trailing PE: 21.9
5-Year Average: 17.6
BSE Sensex Index Average: 22.9
Pharmaceuticals Group Average: 36.5

FORWARD PE
The most recent week's close price divided by the sum of the four upcoming quarterly consensus estimates.

Forward PE: 18.0
5-Year Average: 16.1
BSE Sensex Index Average: 21.3
Pharmaceuticals Group Average: 29.6

FORWARD PEG
The Forward P/E divided by the five-year forecasted growth rate.

Forward PEG: --
5-Year Average: --
BSE Sensex Index Average: 1.3
Pharmaceuticals Group Average: 1.6

This valuation data is not available

CAPLIN POINT LABORATORIES (CAPLIPOINT-IN)
Pharma. & Medical Research / Pharmaceuticals / Pharmaceuticals
**RISK**

**POSITIVE OUTLOOK:** Consistent return patterns (low volatility).

**Risk Score Trend (4-Week Moving Avg)**

<table>
<thead>
<tr>
<th></th>
<th>2020-11</th>
<th>2021-11</th>
<th>2022-11</th>
<th>2023-11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutral</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**RISK INDICATORS**

**Magnitude of Returns** (25% weight)

- **Positive**
  - PGHL: 10
  - SANOFI: 8
  - STAR: 7
- **Neutral**
  - PGHL: 8
  - SANOFI: 9
  - STAR: 8
- **Negative**
  - PGHL: 6
  - SANOFI: 5
  - STAR: 6
- **No Rating**

**Volatility** (25% weight)

- **Positive**
  - PGHL: 10
  - SANOFI: 9
  - STAR: 8
- **Neutral**
  - PGHL: 8
  - SANOFI: 9
  - STAR: 8
- **Negative**
  - PGHL: 6
  - SANOFI: 5
  - STAR: 6

**Beta (1-year) (25% weight)**

- **Positive**
  - PGHL: 9
  - SANOFI: 9
  - STAR: 9
- **Neutral**
  - PGHL: 9
  - SANOFI: 9
  - STAR: 9
- **Negative**
  - PGHL: 9
  - SANOFI: 9
  - STAR: 9
- **Correlation (25% weight)**

The table above shows the risk scores for various metrics such as magnitude of returns, volatility, beta, and correlation, with specific values for each company and index.

**HIGHLIGHTS**

- Caplin Point Laboratories currently has a Risk Rating of 9 while the S&P BSE SENSEX index has an average rating of 9.7.
- On days when the market is up, CAPLIPOINT tends to underperform versus the S&P BSE SENSEX index. Also, on days when the market is down, the shares generally decrease more than the index.
- In both short-term and long-term periods, CAPLIPOINT has shown average correlation (>0.2 and <0.4) with the S&P BSE SENSEX index. Thus, this stock would provide only average levels of diversification to a portfolio similar to the broader market.
- Over the last 90 days, CAPLIPOINT shares have been more volatile than the overall market. The stock’s daily price fluctuations have exceeded that of all S&P BSE SENSEX index firms.
PRICE MOMENTUM

NEUTRAL OUTLOOK: Performance relatively in-line with the market.

Price Momentum Score Averages

<table>
<thead>
<tr>
<th>Pharmaceuticals Group:</th>
<th>3.4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharma. &amp; Medical Research Sector:</td>
<td>3.4</td>
</tr>
<tr>
<td>BSE Sensex Index:</td>
<td>4.1</td>
</tr>
</tbody>
</table>

Currency in INR

Price Momentum Score Trend (4-Week Moving Avg)

Positive Neutral Negative

2020-11 2021-11 2022-11 2023-11

PRICE MOMENTUM INDICATORS

Relative Strength
(50% weight)

- CAPLIPOINT
- STAR
- SANOFI
- PGHL
- WOCKPHARMA

Seasonality
(50% weight)

- CAPLIPOINT
- BSE Sensex
- STAR
- SANOFI

Relative Strength Indicator (Scale from 1 to 100)

CAPLIPOINT Industry Avg

<table>
<thead>
<tr>
<th></th>
<th>Last 10 Days</th>
<th>Last 50 Days</th>
<th>Last 200 Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAPLIPOINT</td>
<td>64</td>
<td>57</td>
<td>55</td>
</tr>
<tr>
<td>Industry Avg</td>
<td>51</td>
<td>52</td>
<td>52</td>
</tr>
</tbody>
</table>

Average Monthly Return (Last 10 Years)

Company Avg 0.59% 0.76% 5.0%

Industry Avg 3.3% 5.4% 1.1%

Industry Rank 58 of 98 51 of 98 73 of 98

PRICE PERFORMANCE

Daily close prices are used to calculate the performance of the stock as compared to a relevant index over five time periods.

- 1-Week: CAPLIPOINT 7.5%, BSE Sensex 2.2%
- 1-Month: CAPLIPOINT -1.6%, BSE Sensex 1.6%
- 3-Month: CAPLIPOINT 10.2%, BSE Sensex 53.9%
- YTD: CAPLIPOINT 6.8%, BSE Sensex 48.8%
- 1-Year: CAPLIPOINT 6.2%, BSE Sensex 57.527

- On 2023-11-08, CAPLIPOINT closed at 1,097.50, 4.1% below its 52-week high and 90.9% above its 52-week low.
- CAPLIPOINT shares are currently trading 4.8% above their 50-day moving average of 1,046.92, and 32.1% above their 200-day moving average of 830.78.
- The S&P BSE SENSEX index is currently 4.2% below its 52-week high and 13.0% above its 52-week low.
Mean Estimate Trend
The mean estimates show how the consensus has changed over the past 30 days and 90 days for the upcoming two quarters (when available) and two years. The percentage change is calculated for the company as a means for comparison by measuring the difference between the current consensus estimate and that of 90 days ago.

Analyst Recommendations
The I/B/E/S Mean is the average recommendation of all analysts covering the stock, as provided by I/B/E/S, the Institutional Brokers Estimate System, from LSEG. The recommendations are presented on a five-point standardized scale: strong buy, buy, hold, sell, and strong sell.

Earnings Surprises
● The surprise summary includes the total number of time periods (and percentage) in the last 12 quarters (quarterly) or last 4 years (annual) in which earnings surprises were positive, negative, or in-line. In order to be recognized as a positive or negative surprise, the percent must be greater than 2% above or 2% below the consensus, respectively.
● The surprise detail section includes a listing of the company’s quarterly earnings reported for the most recent 6 periods (quarters or years). The consensus analyst estimate is provided to determine if the actual earnings report represented a positive surprise, negative surprise, or in-line result.

Fundamental
The Fundamental Rating is based on a combination of four fundamental component factors: profitability, debt, earnings quality, and dividend. Companies that do not pay a dividend are not penalized. Each factor is equally weighted. Then, equal deciles are used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A stock needs to have at least two of the four fundamental factors present in order to receive a score.

Profitability
● Revenue Growth: (Net Sales - Previous Net Sales) / Previous Net Sales
● Gross Margin: Gross Profit / Net Sales
● Return on Equity: Net Income / Total Equity
● Net Margin: Net Profit / Net Sales

Debt
● Current Ratio: Current Assets / Current Liabilities
● Debt-to-Capital: Total Debt / Total Capital

Interest Coverage: (Interest Income + Preferred Cash Dividends) / Funds from Operations
● Interest Coverage: Earnings before Interest and Taxes / (Interest Income + Preferred Cash Dividends)

Earnings Quality
● Operating Cash Yield: Operating Cash Flow / Net Income
● Accruals: (Net Income - Operating Cash Flow - Investing Cash Flow) / Average Net Operating Assets
● Days Sales in Inventory: 365 / (Cost of Goods Sold / Inventory)
● Days Sales in Receivables: 365 / (Net Sales / Receivables)

Dividend
The company must have a current dividend yield.
● Dividend Growth Rate: (Dividends per Share - Previous Dividends per Share) / Previous Dividends per Share
● Dividend Coverage: (Pre-Tax Income + Interest Expense) / (Interest Income + Dividends)
● Dividend Yield: Annual Dividends per Share / Current Market Price per Share

Indicator Trend
The fundamental indicator trend displays either quarterly scores over the past three years or annual scores over the past six years, depending on the reporting periods for the country. The best and worst scores can be easily determined from the values shown on the chart for each quarter or year.

Relative Valuation
The Relative Valuation Rating is based on a combination of three component factors: Price to Sales, Trailing P/E, and Forward P/E. Each factor is equally weighted. Equal deciles are then used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. These common valuation metrics are evaluated against the overall market, the index, and the company’s own historic 5-year averages. A stock needs to have at least one of the three relative valuation factors in order to receive a score.
● Price to Sales: Close Price / (Sales for 4 Quarters or 1 Year / Shares Outstanding)
Trailing P/E: Close Price / Most Recent 4 Quarters or 1 Year of Earnings
Forward P/E: Close Price / Upcoming 4 Quarters or 1 Year of Earnings

Valuation Averages
Negative values are excluded when calculating the averages. A maximum value of 100 is placed on Trailing P/E and Forward P/E, a maximum value of 5 is placed on Forward PEG, and a maximum value of 20 is placed on Price to Sales when calculating the averages. Higher values are rounded down to the maximum for the averages.

Valuation Multiples
The valuation multiples provide the Trailing P/E, Forward P/E, Forward PEG, and Price to Sales for the company and the relevant index average. In addition, a comparison of the current company's values to its 5-year average and an industry average are presented. A discount occurs when the company's ratio is valued more favorably (lower) than that to which it is compared.

Risk
The Risk Rating displays stocks on a scale of 1 to 10 with 10 being awarded to the least risky stocks. It is derived by looking at a series of long-term (5-year) and short-term (90-day) stock performance measures including volatility, magnitude of returns, beta, and correlation. Each factor is equally weighted. Then, equal deciles are used to rank each stock across the market. A stock needs to have at least two of the four risk factors in order to receive a score.

• Magnitude of Returns - The best / worst daily returns in the past 90 days and the best / worst monthly returns in the past 60 months.
• Volatility - The standard deviation of the stock price over the last 90 days and last 60 months, along with the average and largest intra-day stock swing.
• Beta - Measures the tendency of a security's returns to respond to swings in the market, based on the beta of the company versus the relevant index.
• Correlation - Determines how closely the returns of the stock and the relevant index move together, measured over the last 90 days and last 60 months.

Risk Analysis
Price analysis for the company and the relevant index is provided over two time periods. Daily analysis is provided for the last 90 days, whereas monthly statistics are used for the last 60 months.

Price Momentum
The Price Momentum Rating is based on a combination of two technical performance factors: relative strength and seasonality. The factors are equally weighted. Equal deciles are then used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A stock needs to have data for the relative strength factor in order to receive a score.

• Relative Strength - The relative strength of the company for the last 10 days, 50 days, and 200 days on a scale of 1 to 100.
• Seasonality - The average monthly return (price performance) for the current month and next 2 months for the company and industry, over the past 10 years. A lower industry rank indicates a higher return.

Price Performance
Daily close prices are used to calculate the price performance of the stock. The performance of the relevant index is also displayed as a means of comparison.

DISCLAIMER
© 2023 Refinitiv, an LSEG business. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. All information in this report is assumed to be accurate to the best of our ability. Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions taken in reliance on such content.

Any forward-looking statements included in the Refinitiv content are based on certain assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from current expectations. There is no assurance that any forward-looking statements will materialize.

The content in this Refinitiv report does not constitute investment advice or a recommendation to buy or sell securities of any kind. Past performance is not a guarantee of future results. Investors should consider this report as only a single factor when making an investment decision.